Clinical trial NCT02704793: Cerebellar rTMS for Essential Tremor
Official title: Assessing Clinical Effectiveness of Cerebellar Repetitive Transcranial Magnetic Stimulation (rTMS) on Severity of Motor Signs of Essential Tremor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Essential Tremor
Lead sponsor: Mashhad University of Medical Sciences
Sponsor class: OTHER
First posted: 2016-03-10
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Essential tremor (ET) is a low-mortality, though truly burdensome and debilitating condition which is known to be the second most common movement disorder of the adult population only after restless legs syndrome. The prevalence of the disorder in all age groups has been estimated to be 0.9%. Repetitive transcranial magnetic stimulation (rTMS) is an almost safe technique which has been used in diagnosis and treatment of many neurologic and psychiatric conditions. Recent studies have shown that cerebellum has a significant role in development of ET and that rTMS could exert therapeutic effects on its motor symptoms. In this study researchers will recruit at least 30 subjects among patients visiting at the Specialty Clinic of Mashhad Medical University according to researchers exclusion and inclusion criteria and after signing a written informed consent, will randomly be assigned to either real or sham rTMS. On the real rTMS arm, patients will be treated with 900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere for 5 consecutive days and sham treatment will be performed with the same protocol using a small device placed on the TMS coil (not visible to the patients) producing electrical stimulation (less than 3 mili amperes), to simulate the sensation of real TMS. Subject's ear will be protected with earplugs during both real and sham stimulations. After 2 months of follow-up, patients will undergo crossover and receive the other treatment as described above. Patients would be assessed using Fahn-Tolosa-Marin scale at the baseline and again on days 5, 12, and 30 after each real or sham treatment session by a blinded researcher. Data will be analysed by another researcher who is also blind.


Eligibility criteria: Inclusion Criteria:

* having a diagnosis of essential tremor (ET) based on Movement Disorder Society criteria, involving at least one hand.
* 18 years or above
* cognitively eligible to give informed consent of participation in the trial.

Exclusion Criteria:

* Cardiac pace-maker or other implanted magnetic device or having other contraindications of performing a routine non-contrast MRI
* skin defect at the occipital area preventing placement of a coil
* Currently pregnant or plan for pregnancy in the next 6 months
* History of seizure
* Other comorbid medical conditions capable of producing or enhancing tremor
* advanced cardiac, renal, hepatic or other disabling conditions making patient physical unable to participate in examination and receiving the intervention
* Use of new drugs with potential effect on tremor

Primary outcomes:
measure: change in score of Fahn-Tolosa-Marin scale
timeFrame: at the baseline and on days 5, 12, and 30 after each real or sham treatment session.
Secondary outcomes:
Other outcomes:
Locations:
city: Mashhad
country: Iran, Islamic Republic of
facility: Department of Neurology, Ghaem Hospital
state: Razavi Khorasan
Study officials:
affiliation: Mashhad University of Medical Sciences
name: Ali Shoeibi, MD
role: STUDY_DIRECTOR
References: